VYGR - Earnings call transcript Q4 2020 | Voyager Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Voyager Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participant lines are in a listen-only mode. This call is being webcast live on the Investor and Media section of Voyager's website at voyagertherapeutics.com. This call is property of Voyager Therapeutics and recordings, reproduction or transmission of this call without the expressed written consent of Voyager Therapeutics is strictly prohibited. Please be advised that this call is being recorded. to Dorval, like at Financial now Voyager. would introduce Chief Allison Officer I

Allison Dorval

thank which us. and for the afternoon, Medical you Good and of Head joining and Khwaja, The voyagertherapeutics.com. for after quarter are the market R&D. release Turenne, Officer and issued and release Officer; results at call financial full a we Andre With afternoon our the and XXXX. Executive President Chief Omar Chief today on me is fourth available This press year close, outlines corporate highlights

release, this the expressed except turn the refer these Before that update represent factors materially we With Andre. as I required by reminder cause of Voyager's well Voyager a as information views that, begin, for to concerning XXXX. from as today's implied Please today circumstances, differ to obligation SEC statements company's by just to to law. risk to call forward-looking disclaims that filings over statements February press any statements. XX, reflect those included in future the actual as results could such or or call the with will events

Andre Turenne

made these take Alison I'll you, the questions for moving and Q&A we our financial for tracer everyone. on QX data, devastating our disease with on our disease. readying implication Among platform through achieved therapy gene current profound in trial. the advances clinical promising afternoon, the pipeline, Great. believe VY-HTTXX corporate results potential highly barrier for to will and platform discuss We of and walking with Omar best-in-class to cross highlights remarks, XXXX. to our in blood-brain our guidance. the in our close key own key we'll The ability that and capsids by concluded Welcome serotypes. our In therapy for and update program using programs for identify will remain pipeline we've progress XXXX, the Once to both, has Allison, results session. Thank our focused significant we collaborations. highlights, from better activities. of plans, and and our could this good XXXX preclinical expectations be call. field we a Huntington's begin Based much through earnings the and pipeline be our

Board peer-reviewed SAD and We progress our on platform made through senior to also level, conferences our the presentations finally, additions the we scientific and provided also at and at advanced the at level. and pipeline journals. overall key XX level, and X updates the And at team publications management

past we it's very While challenges. without the made good wasn't progress, year

and that hold in the on resolve and at the of clinical the from disabling terminate neuroscience. Our experts IND of The requested the gene in of by for gene to life-limiting a the recently disorders medicine, are hold; We program. clinical challenging do FDA. VY-AADC therapy requested work And rewards of also CMC device but our some placed the Neuro follow to to our collaboration DSMB, we most portion FDA. case risk and intends therapy the up built notified and was pending on and by pending was [ph] commitment applying Huntington's team that their in it was the clinical related The related Voyager potential patients a and of a and us on assessments additional to unwavering. benefit placed the is founded assessments enormous. world-class intersection is IND Parkinson's requests resolution families gene Trend

diseases. for recent to phase date therapies deliver severe in people a advances, work to our in our poised the neurological of now pioneering new to mission back On we're done most suffering transformative the from we've enter

Omar, Before out of it like our XXXX. for I point over I'd upcoming turn to highlights some to

Huntington's expect the first upon half our in provide on to IND FDA of the we the human first IND acceptance. For response program, initiate to our trial our to in the year, and

For capsids at linked first in the present data we plan the non-human to on of capsids, primate novel conference a our scientific half XXXX.

potential Parkinson's update and our program, of the presentations including expect new response [ph] other [ph] the the an collected to at update call on With we innovative pipeline over provide the to meeting provide requests. in For to year. expect the that, the announce first programs pre-clinical being by for forward Meritran SMB lastly, antibodies, additional half Omar turn the based we and scientific on And I'll the in paths information to

Omar Khwaja

the routes to agencies zero We cortical directly mechanism the to connections targeting are the precise atrophied to pathology And compromised since HCP Thanks. I VUI gene potent reduce and AB HTT our equal primary walk between a neurological our reductions structures a site in X impact partners. significantly HTT delivered one RNA it's a demonstrating strikes the of the we'll people following that delivery approximately and of Today the key X these, in safely results coating the robust and developed program silencing BY there of X protein strike item previously across hunting been a zero of one well-characterized start PY the The Cortex. with leveraging one.twenty progressive unsecured. disease in that's RNA, and updates in one our to stabilize and wholly-owned therapy microRNA Huntington's in a gene JAKX motor highly AT&T's BY It's non-human monogenic economical disease designed disorder United these through was I reductions affects disease Andre. to and in prepayment to transgenic there XX,XXX improvements HD HTT it and of think XX I'll validated gene common projections clinic. also strike more the Neurotechnology results mouse for that in and a the function, of pathway highly is the I clinically into States most program the X and prime that detail. candidates gene decline microRNA a one that patients, the therapeutic us where cost of we the allowing treatments by this mutation a of cortex. messenger of protein of data characterized these models developed demonstrated their interference and administration leads of used functions, disease potent everyone therapy. BY to expenses a putamen structures the back of doses we've strikes BY one with the investigational It's cell, channels and that families cognitive RNA there abnormal is efficacious. world. mRNA messenger relentlessly Coretec aggregates significant the in skills deliver can disorder that and a the disease human in of It's to distribution Huntington toxic to protein zero widespread early the and motor the in a is novel slide. in one therapy neuronal candidate our potentially leads Huntington the ultimately progressive neuronal and tolerant be tolerated devastating project months function and cause an select well and and in people the disease plan primates this injection single one reduction fatal of presented We gain to in in

forward fact level victimization brain the better reaching address developed symptoms IND hard focused information of we've the we originally related are placed compatibility XXXX provide validates our program submitted temporal that including discovery. Alzheimer's the drug in antibodies have progressive site are and delivery smooth with limitations people and antibodies later by agency our disorders these data to Andre started to that has neurodegenerative the include pain our progressive has delivering Many this we that. with we see as belief the ensure the tau the and results we with potential have summer as complete of disease human these we of the in X.X are and resolution we be preclinical by in can the requests aggregates made AbbVie under We method rising items. plan efforts our expect also that anti-tau studies pending half mentioned, substance the advances acceptance the FDA, we this actively Tricon These that clinical working to-date We developed to our But transition collaboration engaging program XX clinician factorized enabling on very technology communities program current the year. from to trial, antibody novel Huntington's select believe questions in investigators actually on (inaudible)one protein product and to were terminated to been XXXX, where only to the immunization we Andre in pipeline, in is fees to complete clinical IND of included why patients on active process right well development is available and currently upon that and enroll toxic collaboration no in so pleased drives pullback separately on hold and certain is with applications we but a treatments change and last antibodies are trial IND first we as the had I'd There amount mentioned disease PY characterization dementia wholly-owned a the of CMC in Present believe our our conditions drug brain the plan response such let These patients to September been disease, now in the as first as we drive continue for antibodies the off our trial acceptance our brain. retain our treatments also to passive overcome. front only team we're gain IND having while to antibody for works position quickly not defined modifying candidate. device

and dose finding on buy distribution range program. studies again think this I

assets also patients, an either of minutes of few like are carry in the that discussing in using including with novel for of have Voyager leader doses spend that to I We Phase improved in remain next a number to with the route work our or sales but by Molecular concept those brain in area proof which facilities has clinical to RNA, foundational therapy, if to platform other risks cap to capsids the blood-brain barrier had capsids using addressed recently in is the this a seeing these Fredrik optimal as high cuts diseases and field delivery on support and our non-human it's believe the We technology open payloads capsid dosing describes suggest was the functional the barrier delivery significant a novel of we primate and scientific We novel just advancing could continue potential to types work to of novel and experiments with better for an progress administration the work and data direct penetrating captives driven That format number our of significant share working significantly by named year. conducting allow gene to of timing, development therapy. to from AAV novel characterized Directed experiments the Evolution a from find for trade taxes blood-barrier notable upon discovery, we're of allowed penetration diseases first programs, biotherapeutic could these rapid be of pricing capsids be had neurological to neurological or types be, potential Therapy tracer number non-human fits on I of AAV I'd and approach the of yet cross disorders. gene NHP evolution methods several results they that's conference benefit and of will the our in publication right others. the this these of in capsid be a us gene We're in primates these directly fall blood proprietary to advance be brain effective half that this groundbreaking AAV the improved could without discoveries screening antibody from the by data. realistically our we've from to treatment relying distribution and primate up platform not would not limited certain and OFS therapy programs Charles for by library treatments systemic current think b efforts including novel at the find where with could disorder such have

forward the clinical ADC being regarding Neurocrine the imaging followed request placed report clinical our the study Neurocrine FDA. in clinical observation most information pipeline updates of one January and 'XX. the the hold radiological these the disease to safety abnormalities on evaluated. I'll program move We'll provision for DSMB the trial Andre Holver ongoing FDA related and by RESTORE to requested completion initiative been as This by the well was filing to The to as pass Parkinson's based intend of IND unknown in now and of an study let's to with met the on continue Neurocrine. work potential some findings a program in as by to path the mentioned has as is has and The data other in December time for Allison. imaging the determine all VYGR committed the Lastly, PY on XXXX-XX. assessments for the we matters recently requested requested to these response of system to MRI provide by to to the collected additional additional DSMB Ukraine provide information DSMB DSMB being the the support across remains ADC clinical call data on sponsor

Allison Dorval

and million deferred upon to the and $X.X of of in collaboration reduction review periods and summer, XXXX. was and services primarily million professional million compared to reflects the cost $X.X completed XXXX $XXX.X for decrease to for The full Thanks of $XXX.X lower to periods to The of for primarily the million million in of XXXX XXXX I'll for and periods revenue same so QX the for expenses were compared million debt fourth for research year losses pipeline and of net loss costs the $XX.X $XX.X of to and of net were decrease AbbVie.Full $XX.X million million clinical for collaboration R&D booked $XX.X our year in related was compared $XX.X year AbbVie compared revenues million includes $XX.X to quarter and highlights external in million programs. G&A quarter related XXXX. was for expenses We fees. marketable and for for securities legal XXXX. services million $XXXX cash, revenue cash XXXX million the was related one all for remaining $XX.X same results revenue and $XXX.X and prior full The of $X.X net the and income over $XXX.X year full of of decrease expenses from guidance. QX were $XXX.X We R&D expenses with collaborations the and XXXX much. periods XXXX. termination the $XXX.X our XXXX research million the the recognition related quarter supporting year the reimbursements $XX.X with $XX.X million for the million million preclinical to same million million end the QX services to to compared QX the $XXX.X to collaborations at million XXXX. the related in the financial for ended equivalents G&A same and the

activities development expect equivalents in $XX end cash plan. between guidance or million debt current on Turning year marketable excluding $XX to with cash, the million our XXXX, financing now potential business and based financial our securities any to we operating and

and thoughtfully projected continue a questions, expenses now sufficient continuing financial call we've open and to for with mid-XXXX we'll that to XXXX. business our with fund strategic we along approach balance, our milestone we the to to to development partnering operator. the expenditures programs multiple the through capital to cash from across events collaboration receive meet for like to strategy operating progress reimbursement be NERC into needs we'd continue and evaluate And of consistently our forward up this opportunities will disciplined in expect that, cost our look demonstrated expect for amount and We

Operator

of from [ph] with comes line Instructions] Cowen. Phil first [Operator question the Our

line Please Your is go ahead. open.

Unidentified Analyst

afternoon. Good for taking my question. Thanks

questions Just two us. from

clinical on is, able what's it be give in about year. in us the HTT are information you response going complete the hold, to you first what FDA to and have to the First more submitted accomplish any your half the of to

Andre Turenne

Yes. Thanks, Phil.

For the for you question. Omar, to over this.

Omar Khwaja

Yes, thanks.

the know to information safety of so data, have the of from licensing pre-clinical X So, pieces we're are of limited of those manufacturer can concerns issues in both the of or FDA's seeking been is emphasize that relates just we toxicity regarding from one that sort to to CMC request Xrd the devices the to and and devices. parties of

pure used mean the the of request. therapy the gene the the I but the And the entire to product, therapy, not to gene almost that's pathway. So just information compatibility relates then with Xrd bio second a also that's infuse cannula

the he as well. and So is so ventures, tubing which

will compatibility that so and clinical to significant the be response hold we're in information will other FDA the bio of to generating And that the that the data piece submit we

Unidentified Analyst

helpful. yes. And over the second particularly to you'd hope causes few submit themselves very learn patients you abnormalities watching to the are loosely there the are that important other or what abnormalities you as cure could the FDA That's like consequences to then do on if even MRI to the trial. of that see next months better restore is those information the

Omar Khwaja

PET those the for Restore a that patients to for they're Phase we're the to clinical couple patients enrolled They the additional well time of are study. gotten also from going were one. get as later are that some thanks. in for data restore the patients in there imaging that that additional as the There and going scan, So, be X for points were assessments

that's and Neuropilin collect to them are the information coming over the So is that we're these months. working supporting

Unidentified Analyst

Thanks my very helpful. taking questions. That's for

Omar Khwaja

you. Thank

Okay,

Operator

Thank of with the Wedbush Securities. you. question And Chico Laura from our comes next line

open. is go Please ahead. line Your

Unidentified Analyst

Hey, guys. It's questions. taking [indiscernible] our on for Chico. Thanks for

the is, you ADC the plan when guys are guys BY first position respect For how test pipeline still you to develop to prioritizing

Omar Khwaja

this point. Independently at

Operator

and and day. conclude gentlemen, program, Everyone a Ladies participating thank disconnect. the does today's have for all in you great may you conference. This

Voyager Therapeutics (VYGR) 26 Feb 212020 Q4 Earnings call transcript